Aerie Pharmaceuticals trades as part of the drug manufacturers industry and is in the healthcare sector. The company CEO is Vicente Anido. Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is engaged in the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Previous Intraday Performance:
The AERI shares had a previous change of 1.09% which opened at 39.78 and closed at 39.87. It moved to an intraday high of 40.25 and a low of 39.06.
SeekingAlpha: Aerpio Pharmaceuticals: Eye Spy An Opportunity
Historical Performance:
Over the last five trading days, AERI shares returned 1.84% and in the past 30 trading days it returned -4.82%. Over three months, it changed 0.66%. In one year it has changed -20.85% and within that year its 52 week high was 74.75 and its 52 week low was 32.18. AERI stock is 23.90% above its 52 week low.
Our calculations result in a 200 day moving average of 47.83 and a 50 day moving average of 42.56. Right now, AERI stock is trading -16.63% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
SeekingAlpha: Aerpio Pharmaceuticals: Eye Spy An Opportunity
Liquidity:
The company has a market cap of $1.8b with 45.9m shares outstanding and a float of 45.2m shares. Trading volume was 275,979 shares and has experienced an average volume of 572,429 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Aerie Pharmaceuticals was -5.52 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.84.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr 2019 | -1.06 |
|---|---|---|
| 4th | Qtr 2018 | -1.14 |
| 3rd | Qtr 2018 | -1.96 |
| 2nd | Qtr 2018 | -1.40 |
| 1st | Qtr 2018 | -1.05 |
Base on our calculations, the intrinsic value per share is 221.38, which means it might be undervalued and has a margin of safety of 81.99%.
The long-term trend of the EPS is a vital number as it helps understand the future potential of Aerie Pharmaceuticals.
Indicators Also to Watch:
The beta was calculated to be 0.80.
SeekingAlpha: Aehr Test Systems jumps 23% post Q3 results
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -117.74%, return on assets is -77.46%, price-to-sales is 51.69 and price-to-book is 9.53.
Company Score Card:
Results are out of six:
5 : Growth Expectations Result
3 : Financial Safety Result
0 : Past Performance Result
2 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result
Related Tags: AERI, Aerie Pharmaceuticals, Drug Manufacturers, Healthcare
